Amy Baxter is a writer and editor specializing in environmental and energy topics. She has written for publications such as Environment+Energy Leader and has been featured in Environmental Leader. With a focus on sustainability, clean energy, and climate change, Amy's work explores the latest developments and challenges in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Amy Baxter's coverage is heavily focused on energy and sustainability, with a strong emphasis on industry developments and corporate announcements. To effectively reach out to her, provide newsworthy updates from the renewable energy sector, innovative sustainable solutions or breakthroughs in technology related to climate change. Expert commentary from professionals directly involved in these areas will likely catch her attention.
Considering that Amy's focus is largely based around official statements and private sector announcements, providing exclusive insights or data-backed stories about emerging trends or significant advancements within the energy and sustainability sectors could be particularly compelling for her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Digital pioneers harnessing the data to improve pharma’s outcomes.
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
By: Amy Baxter
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
By: Amy Baxter
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump administration.
Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate if given a role in the incoming Trump administration.
By: Amy Baxter
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck Congress may mean its timeline for passage slips back.
(833) 317-6278 
